SAN DIEGO, CA - March 5, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), today released the following note authored by its Chairman and CEO, Jim Joyce. Dear ...
Sigyn Therapy™ is a Candidate to Treat Sepsis and Other Life-Threatening Inflammatory Conditions That Are Not Addressed with Approved Drugs SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- via ...
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory ...
Sigyn is Focused on the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions That are Not Addressed with Approved Drug Therapies Trading to Commence Tomorrow Under the Ticker Symbol ...
Blood purification technologies have emerged to become leading post-exposure countermeasures to treat emerging pandemic viruses. When properly designed, these devices can also serve a dual-use purpose ...
SAN DIEGO, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire-- Sigyn Therapeutics, Inc. (SIGY), a development-stage medical technology company, today announced that a 1-for-40 reverse split of ...
SAN DIEGO, CA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage medical technology company focused on addressing unmet needs in global ...
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback